+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Respiratory Tract Infection Therapeutic Market by Drugs (Antibiotics, Cough Suppressants, Nasal Decongestants), Disease Indication (Lower Respiratory Tract Infection, Upper Respiratory Tract Infection), Distribution Channel - Forecast 2024-2030- Product Image
Global Respiratory Tract Infection Therapeutic Market by Drugs (Antibiotics, Cough Suppressants, Nasal Decongestants), Disease Indication (Lower Respiratory Tract Infection, Upper Respiratory Tract Infection), Distribution Channel - Forecast 2024-2030- Product Image
Sale

Global Respiratory Tract Infection Therapeutic Market by Drugs (Antibiotics, Cough Suppressants, Nasal Decongestants), Disease Indication (Lower Respiratory Tract Infection, Upper Respiratory Tract Infection), Distribution Channel - Forecast 2024-2030

  • PDF Icon

    Report

  • 196 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 4985879
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Respiratory Tract Infection Therapeutic Market size was estimated at USD 45.33 billion in 2023, USD 48.83 billion in 2024, and is expected to grow at a CAGR of 7.80% to reach USD 76.70 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Respiratory Tract Infection Therapeutic Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Respiratory Tract Infection Therapeutic Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Respiratory Tract Infection Therapeutic Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Apotex Inc., AstraZeneca PLC, Aurobindo Pharma Limited, Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., Fresenius SE & Co. KGaA, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Merck & Co., Inc., Novartis AG, Pfizer Inc., Piramal Enterprises Ltd., Teva Pharmaceutical Industries Ltd., and WG Critical Care, LLC by PharmaSphere Ltd.

Market Segmentation & Coverage

This research report categorizes the Respiratory Tract Infection Therapeutic Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drugs
    • Antibiotics
    • Cough Suppressants
    • Nasal Decongestants
    • Non-Steroidal Anti-Inflammatory Drugs
  • Disease Indication
    • Lower Respiratory Tract Infection
    • Upper Respiratory Tract Infection
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Respiratory Tract Infection Therapeutic Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Respiratory Tract Infection Therapeutic Market?
  3. What are the technology trends and regulatory frameworks in the Respiratory Tract Infection Therapeutic Market?
  4. What is the market share of the leading vendors in the Respiratory Tract Infection Therapeutic Market?
  5. Which modes and strategic moves are suitable for entering the Respiratory Tract Infection Therapeutic Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Respiratory Tract Infection Therapeutic Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increased reports cases of asthma and respiratory tract infection
5.1.1.2. Changing Lifestyle and geriatric population
5.1.1.3. Increase development of generic drugs and biosimilars in the space
5.1.2. Restraints
5.1.2.1. Seasonal indications and inspections
5.1.3. Opportunities
5.1.3.1. Investment in drug development and commercialization
5.1.3.2. Technology development in drug delivery systems
5.1.4. Challenges
5.1.4.1. Emergence of antimicrobial resistance
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Respiratory Tract Infection Therapeutic Market, by Drugs
6.1. Introduction
6.2. Antibiotics
6.3. Cough Suppressants
6.4. Nasal Decongestants
6.5. Non-Steroidal Anti-Inflammatory Drugs
7. Respiratory Tract Infection Therapeutic Market, by Disease Indication
7.1. Introduction
7.2. Lower Respiratory Tract Infection
7.3. Upper Respiratory Tract Infection
8. Respiratory Tract Infection Therapeutic Market, by Distribution Channel
8.1. Introduction
8.2. Hospital Pharmacies
8.3. Online Pharmacies
8.4. Retail Pharmacies
9. Americas Respiratory Tract Infection Therapeutic Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Respiratory Tract Infection Therapeutic Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Respiratory Tract Infection Therapeutic Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. Abbott Laboratories
13.1.2. Apotex Inc.
13.1.3. AstraZeneca PLC
13.1.4. Aurobindo Pharma Limited
13.1.5. Bristol Myers Squibb Company
13.1.6. F. Hoffmann-La Roche Ltd.
13.1.7. Fresenius SE & Co. KGaA
13.1.8. GlaxoSmithKline PLC
13.1.9. Hikma Pharmaceuticals PLC
13.1.10. Merck & Co., Inc.
13.1.11. Novartis AG
13.1.12. Pfizer Inc.
13.1.13. Piramal Enterprises Ltd.
13.1.14. Teva Pharmaceutical Industries Ltd.
13.1.15. WG Critical Care, LLC by PharmaSphere Ltd.
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET RESEARCH PROCESS
FIGURE 2. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2023 VS 2030
FIGURE 3. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET DYNAMICS
FIGURE 7. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2023 VS 2030 (%)
FIGURE 8. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2030 (%)
FIGURE 10. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 12. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 6. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUGH SUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NASAL DECONGESTANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 11. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 14. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 18. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 19. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 20. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 21. ARGENTINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 22. ARGENTINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 23. ARGENTINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 24. BRAZIL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 25. BRAZIL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 26. BRAZIL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 27. CANADA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 28. CANADA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 29. CANADA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 30. MEXICO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 31. MEXICO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 32. MEXICO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 33. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 37. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 38. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 39. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 40. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 41. AUSTRALIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 42. AUSTRALIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 43. AUSTRALIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 44. CHINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 45. CHINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 46. CHINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 47. INDIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 48. INDIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 49. INDIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 50. INDONESIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 51. INDONESIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 52. INDONESIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 53. JAPAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 54. JAPAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 55. JAPAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 56. MALAYSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 57. MALAYSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 58. MALAYSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. PHILIPPINES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 60. PHILIPPINES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 61. PHILIPPINES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 62. SINGAPORE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 63. SINGAPORE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 64. SINGAPORE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. SOUTH KOREA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 66. SOUTH KOREA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 67. SOUTH KOREA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 68. TAIWAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 69. TAIWAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 70. TAIWAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 71. THAILAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 72. THAILAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 73. THAILAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 74. VIETNAM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 75. VIETNAM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 76. VIETNAM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 81. DENMARK RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 82. DENMARK RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 83. DENMARK RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 84. EGYPT RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 85. EGYPT RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 86. EGYPT RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 87. FINLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 88. FINLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 89. FINLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. FRANCE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 91. FRANCE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 92. FRANCE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 93. GERMANY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 94. GERMANY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 95. GERMANY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. ISRAEL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 97. ISRAEL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 98. ISRAEL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 99. ITALY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 100. ITALY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 101. ITALY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 102. NETHERLANDS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 103. NETHERLANDS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 104. NETHERLANDS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 105. NIGERIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 106. NIGERIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 107. NIGERIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 108. NORWAY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 109. NORWAY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 110. NORWAY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 111. POLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 112. POLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 113. POLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 114. QATAR RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 115. QATAR RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 116. QATAR RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 117. RUSSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. SAUDI ARABIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 121. SAUDI ARABIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 122. SAUDI ARABIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 123. SOUTH AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 124. SOUTH AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 125. SOUTH AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. SPAIN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 127. SPAIN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 128. SPAIN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 129. SWEDEN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 130. SWEDEN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 131. SWEDEN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 132. SWITZERLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 133. SWITZERLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 134. SWITZERLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 135. TURKEY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 136. TURKEY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 137. TURKEY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. UNITED ARAB EMIRATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 139. UNITED ARAB EMIRATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 140. UNITED ARAB EMIRATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 142. UNITED KINGDOM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 145. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SHARE, BY KEY PLAYER, 2023
TABLE 146. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET LICENSE & PRICING

Companies Mentioned

  • Abbott Laboratories
  • Apotex Inc.
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Bristol Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Fresenius SE & Co. KGaA
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Piramal Enterprises Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • WG Critical Care, LLC by PharmaSphere Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages196
PublishedMarch 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 48.83 Billion
Forecasted Market Value ( USD ) by 2030 $ 76.7 Billion
Compound Annual Growth Rate7.8%
Regions CoveredGlobal
No. of Companies Mentioned15

Related Topics

Related Reports

Global Upper Respiratory Tract Infection Treatment Market Report and Forecast 2023-2031 - Product Image

Global Upper Respiratory Tract Infection Treatment Market Report and Forecast 2023-2031

  • Report
  • 160 Pages
  • Global
From
Respiratory Tract Infection Treatment Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Respiratory Tract Infection Treatment Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 97 Pages
  • Global
From
Upper Respiratory Tract Infection Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Upper Respiratory Tract Infection Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 93 Pages
  • Global
From
Global Upper Respiratory Tract Infection Treatment Market 2024-2028 - Product Image

Global Upper Respiratory Tract Infection Treatment Market 2024-2028

  • Report
  • 170 Pages
  • Global
From
Urinary Tract Infection Therapeutics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Image

Urinary Tract Infection Therapeutics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • 112 Pages
  • Global
From

About the Respiratory Tract Infection Drug Market

The Respiratory Tract Infection Drug market is a subset of the larger Respiratory Drugs market. It includes drugs used to treat infections of the respiratory tract, such as bronchitis, pneumonia, and sinusitis. These drugs are typically antibiotics, antivirals, and anti-inflammatory medications. They are used to reduce symptoms, prevent complications, and reduce the spread of infection. The Respiratory Tract Infection Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, GlaxoSmithKline, Merck, Sanofi, AstraZeneca, Novartis, and Johnson & Johnson. Other companies include AbbVie, Bristol-Myers Squibb, and Eli Lilly. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.